P-GemDOx方案一线治疗早期结外NK/T细胞淋巴瘤的疗效、安全性及分层预后分析
该回顾性研究纳入2015年8月至2021年5月南京医科大学第一附属医院收治的60例早期ENKTL患者,评估P-GemDOx方案一线治疗的疗效与安全性。完成4~6周期后ORR为88.3%,CR率76.7%,4年PFS率(66.3±7.1)%、OS率(79.5±6.0)%;PINK/PINK-E各组间生存无显著差异,基于诊断时SUVmax>12.8、非单个鼻腔浸润、4~6周期后未达CR建立的POD24-IPI可分层4年OS(P=0.014)。
要点
- P-GemDOx一线治疗早期ENKTL的ORR为88.3%,CR率为76.7%。
- 4年PFS率为(66.3±7.1)%,4年OS率为(79.5±6.0)%。
- POD24-IPI低、中、高危组4年OS率分别为100%、(85.6±9.7)%、(65.0±10.2)%(P=0.014)。
核心结论
- 在早期ENKTL患者中,P-GemDOx方案是一个安全且有效的一线治疗方案。
- POD24-IPI是一个良好的风险分层模型。
研究设计与样本
- 回顾性分析2015年8月至2021年5月南京医科大学第一附属医院血液科收治的60例使用P-GemDOx方案治疗的早期初诊ENKTL患者的临床资料。
- 使用χ²检验及Fisher确切概率法比较组间临床特征差异,使用Log-rank检验比较组间生存差异,进行生存和预后因素分析。
主要发现
- 60例患者完成4~6个周期P-GemDOx方案治疗后,ORR为88.3%,46例(76.7%)获得CR。
- 4年PFS率和OS率分别为(66.3±7.1)%和(79.5±6.0)%。
- 根据PINK/PINK-E预后评分系统分组,各组间PFS和OS差异均无统计学意义。
- 23.3%的患者24个月内出现疾病进展(POD<24),POD<24组(14例)和POD≥24组(46例)的OS期差异有统计学意义(P<0.001)。
- POD24-IPI低危、中危、高危组4年OS率分别为100%、(85.6±9.7)%、(65.0±10.2)%(P=0.014)。
关键数值与推荐
- POD24-IPI评分:诊断时PET-CT检查存在病灶最大标准摄取值>12.8计1分;非单个鼻腔浸润计1分;4~6个周期治疗后疗效评估未达CR计1分。
- POD24-IPI分层:低危组0分,中危组1分,高危组2~3分。
- P-GemDOx化疗方案临床应用的总体耐受良好,主要不良反应是血液学毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess the efficacy, safety, and related prognostic factors associated with the P-GemDOx regimen as a first-line treatment for patients with early-stage extranodal natural killer (NK) /T cell lymphoma (ENKTL) . Methods: A retrospective analysis was performed on sixty early-stage ENKTL patients treated with the P-GemDOx regimen who were admitted to the First Affiliated Hospital of Nanjing Medical University between August 2015 and May 2021. The Chi-square test or Fisher's exact test was used to compare group differences, and the Log-rank test was used to compare the differences in survival. Survival outcomes and prognostic factors were examined. Results: After completing 4 to 6 cycles of P-GemDOx chemotherapy, the overall response rate (ORR) was 88.3%, with forty-six patients (76.7% ) achieving complete response (CR). The 4-year progression-free survival (PFS) and overall survival (OS) rates were (66.3±7.1) % and (79.5±6.0) %, respectively. According to the PINK/PINK-E model, there was no significant difference in survival outcomes among risk groups. 23.3% of patients experienced progression of disease within 24 months (POD<24). OS estimates differed significantly (P<0.001) between the POD<24 group (n=14) and the POD≥24 group (n=46). Analysis showed that SUVmax > 12.8 at diagnosis, non-single nasal cavity infiltration, and response less than CR after 4-6 cycles all had a significant association with POD24. We used these data as the basis for predicting POD<24 international prognostic index (POD24-IPI). Patients were stratified into low-risk (no risk factors), intermediate-risk (one risk factor), or high risk (two or three risk factors). These groups were associated with 4-year OS rate of 100%, (85.6±9.7) %, and (65.0±10.2) %, respectively (P=0.014). The P-GemDOx regimen was well tolerated, with hematological toxicity being the main side effect. Conclusion: This study demonstrated that the P-GemDOx regimen is effective and safe in the first-line treatment of early-stage ENKTL, and POD24-IPI is a promising prognostic model. 目的: 探讨P-GemDOx方案一线治疗早期结外NK/T细胞淋巴瘤(ENKTL)患者的有效性、安全性以及相关预后因素。 方法: 回顾性分析2015年8月至2021年5月南京医科大学第一附属医院血液科收治的60例使用P-GemDOx方案治疗的早期初诊ENKTL患者的临床资料,使用χ(2)检验及Fisher确切概率法比较组间临床特征的差异,使用Log-rank检验比较组间生存差异,进行生存和预后因素分析。 结果: 60例患者在完成4~6个周期P-GemDOx方案治疗后,总缓解率(ORR)为88.3%,46例(76.7%)获得完全缓解(CR)。4年的无进展生存(PFS)率和总生存(OS)率分别为(66.3±7.1)%和(79.5±6.0)%。根据PINK/PINKE预后评分系统进行分组,各组间PFS和OS差异均无统计学意义。23.3%的患者24个月内出现疾病进展(POD<24),POD<24组(14例)和24个月内未出现疾病进展(POD≥24)组(46例)的OS期差异有统计学意义(P<0.001)。分析POD<24的危险因素,并在此基础上建立了预测POD<24的国际预后指数(POD24-IPI)预后分层模型(诊断时PET-CT检查存在病灶最大标准摄取值>12.8,1分;非单个鼻腔浸润,1分;4~6个周期治疗后疗效评估未达CR,1分;低危组,0分;中危组,1分;高危组,2~3分),低危、中、高危组4年OS率分别为100%、(85.6±9.7)%、(65.0±10.2)%(P=0.014)。此外,P-GemDOx化疗方案临床应用的总体耐受良好,主要不良反应是血液学毒性。 结论: 在早期ENKTL患者中,P-GemDOx方案是一个安全且有效的一线治疗方案;POD24-IPI是一个良好的风险分层模型。.
引用
- Xing TY, Wang WT, Shen HR, et al. [Efficacy and safety analysis of P-GemDOx regimen and stratified prognosis in patients with early extranodal NK/T cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38604793. doi:10.3760/cma.j.cn121090-20230726-00029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。